ALGS
NASDAQ
$5.28
Aligos Therapeutics Inc (ALGS)
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing novel therapies to address unmet medical needs in viral and liver diseases. The company is headquartered in South San Francisco, California.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $56.29 (+966.10%)
Market Cap
$36M
Beta (5Y)
1.99
Price Chart
Valuation
Market Cap$36M
P/S7.59
P/B1.19
Profitability
Total Revenue (TTM)$4.71M
Gross Profit (TTM)-$65M
EBITDA-$95M
Operating Margin-952%
EPS-$14.65
Growth & Risk
FCF 5Y CAGR-0.07%
Beta (5Y)1.99
Sharpe Ratio-0.31